LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Strona główna・Stock List・Johnson and Johnson

Johnson and Johnson

Closed

Sector Healthcare

164.37 -0.29

Buy Sell

Overview

Share price change

24h

Current

Min

164.14

Max

165.88

Key metrics
By Trading Economics
Income	1.4B 4.7B
Sales	1.1B 22B
P/E Sector Avg	21.72 103.001
EPS	2.82
Profit margin	20.873
Employees	131,900
EBITDA	2.1B 7.8B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+4.53 upside

Dividends
By Dow Jones
Next Earnings	15 paź 2024
Next Dividend date	10 wrz 2024
Next Ex Dividend date	18 lis 2024

Market Stats
By TradingEconomics
Market Cap	400B
Previous open	164.66
Previous close	164.37

News Sentiment

By Acuity

41%

59%

90 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

164.13 / 165.71 Support & Resistance

Johnson and Johnson Chart

Related News

20 sie 2024, 12:16 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600 Million

20 sie 2024, 11:43 UTC

Top News

Johnson & Johnson's Rybrevant, Lazcluze Combo Gets FDA Approval for Type of Advanced Lung Cancer

17 lip 2024, 14:14 UTC

Earnings

Trending: Johnson & Johnson Beats 2Q Sales Guidance

4 wrz 2024, 23:20 UTC

Top News

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

23 sie 2024, 20:54 UTC

Top News

J&J Takes Aim at Hospital Drug-Discount Program -- Update

23 sie 2024, 18:09 UTC

Top News

J&J Takes Aim At Hospital Drug-Discount Program -- WSJ

20 sie 2024, 12:41 UTC

Top News

Acquisitions, Mergers, Takeovers

Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion -- Barrons.com

20 sie 2024, 12:01 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600M

20 sie 2024, 11:55 UTC

Acquisitions, Mergers, Takeovers

J&J To Acquire V-Wave For Up To $1.7 Billion In Play For Heart Failure Device -- MarketWatch

20 sie 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Expects the Transaction to Dilute Adjusted EPS by 24c in 2024 and 6c in 2025 >JNJ

20 sie 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Transaction Is Expected to Close Before the End of 2024 >JNJ

20 sie 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Join Johnson & Johnson as Part of Johnson & Johnson MedTech >JNJ

20 sie 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Acquire V-Wave for an Upfront Payment of $600M With the Potential for Additional Regulatory and Comml Milestone Payments Up to $1.1B >JNJ

20 sie 2024, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Acquire V-Wave >JNJ

20 sie 2024, 11:12 UTC

Top News

Johnson & Johnson Wins First FDA Approval For Chemotherapy-Free Lung Cancer Treatment -- MarketWatch

12 sie 2024, 14:30 UTC

Acquisitions, Mergers, Takeovers

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 sie 2024, 09:30 UTC

Top News

Acquisitions, Mergers, Takeovers

Big Drugmakers Are Clinching Smaller Deals -- WSJ

29 lip 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

17 lip 2024, 11:24 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17 lip 2024, 10:43 UTC

Earnings

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson: 2Q Innovative Medicine Worldwide Operational Sales, Excluding Covid Vaccine, Grew 8.8% >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson Updating 2024 Guidance to Reflect Improved Performance and Impact for Recent Acquisitions of Shockwave Medical, Proteologix and NM26 Bispecific Antibody >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson Raises 2024 Operational Sales View to $89.2B-$89.6B Vs Prior View $88.7B-$89.1B >JNJ

17 lip 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

4.53% upside

12 Months Forecast

Average 172.46 USD 4.53%

High 215 USD

Low 150 USD

Based on 14 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Technical Score

By Trading Central

164.13 / 165.71Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

90 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.